/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Our mission is to discover new medicines that improve the lives of people facing serious muscle disease. Our science-driven culture places patients first as we start with their unmet needs and then work towards developing therapies to help address the significant challenges of serious muscle diseases.
$45.32
$1.62 (-3.45%)
EOD Sep 18, 2026
Negative free cash flow of -$144M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$197M
▼ -25.4% YoY
Op. Margin
—
ROIC
-33.94%
▲ +1.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$159M
▼ -30.6% YoY
Op. Cash Flow (TTM)
-$158M
▼ -31.9% YoY
Net Debt
-$69M
Net Cash Position
Cash & Equiv.
$72M
Continue Research
SourceComputed from the 10-Q filed 6 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 7 Aug 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.